参考文献/References:
[1]Yang J,Xu R,Wang C,et al.Early screening and diagnosis strategies of pancreatic cancer:a comprehensive review[J].Cancer Commun (Lond),2021,41(12):1257-1274.[2]Ilic I,Ilic M.International patterns in incidence and mortality trends of pancreatic cancer in the last three decades:A joinpoint regression analysis[J].World J Gastroenterol,2022,28(32):4698-4715.[3]Vincent A,Herman J,Schulick R,et al.Pancreatic cancer[J].Lancet (London, England),2011,378(9791):607-620.[4]Mortazavi M,Moosavi F,Martini M,et al.Prospects of targetingPI3K/AKT/mTOR pathway in pancreatic cancer[J].Crit Rev Oncol Hematol,2022,176:103749. [5]Szymonowicz K,Oeck S,Malewicz NM,et al.New Insights into Protein Kinase B/Akt Signaling:Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response[J].Cancers (Basel),2018,10(3):78.[6]Khan MA,Jain VK,Rizwanullah M,et al.PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges[J].Drug Discov Today,2019,24(11):2181-2191.[7]Zheng C,Tang F,Min L,et al.PTEN in osteosarcoma:Recent advances and the therapeutic potential[J].Biochim Biophys Acta Rev Cancer,2020,1874(2):188405.[8]Schlieman MG,Fahy BN,Ramsamooj R,et al.Incidence, mechanism and prognostic value of activated AKT in pancreas cancer[J].Br J Cancer,2003,89(11):2110-2115. [9]Kesavardhana S,Malireddi RKS,Kanneganti TD.Caspases in Cell Death, Inflammation, and Pyroptosis[J].Annu Rev Immunol,2020,38:567-595.[10]Yue Z,Guan X,Chao R,et al.Diallyl Disulfide Induces Apoptosis and Autophagy in Human Osteosarcoma MG-63 Cells through the PI3K/Akt/mTOR Pathway[J].Molecules,2019,24(14):2665.[11]Hafezi S,Rahmani M.Targeting BCL-2 in Cancer:Advances,Challenges,and Perspectives[J].Cancers (Basel),2021,13(6):1292.[12]Yang J,Zou Y,Jiang D.Honokiol suppresses proliferation and induces apoptosis via regulation of the miR21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells[J].Int J Mol Med,2018,41(4):1845-1854.[13]Abalovich M,Gutierrez S,Alcaraz G,et al.Overt and subclinical hypothyroidism complicating pregnancy[J].Thyroid,2002,12(1):63-68.[14]Apte RS,Chen DS,Ferrara N.VEGF in Signaling and Disease:Beyond Discovery and Development[J].Cell,2019,176(6):1248-1264.[15]Baldini L,Lenci E,Bianchini F,et al.Identification of a Common Pharmacophore for Binding to MMP2 and RGD Integrin:Towards a Multitarget Approach to Inhibit Cancer Angiogenesis and Metastasis[J].Molecules,2022,27(4):1249.[16]Ju R,Zhuang ZW,Zhang J,et al.Angiopoietin-2 secretion by endothelial cell exosomes:regulation by the phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) and syndecan-4/syntenin pathways[J].J Biol Chem,2014,289(1):510-519. [17]Peng Y,Wang Y,Zhou C,et al.PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics:Are We Making Headway?[J].Front Oncol,2022,12:819128.[18]Herrerias MM,Budinger GRS.Revisiting mTOR and Epithelial-Mesenchymal Transition[J].Am J Respir Cell Mol Biol,2020,62(6):669-670.[19]Wang F,Yi J,Chen Y,et al.PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer[J].Acta Histochem,2023,125(6):152071.[20]Annunziata MC,Parisi M,Esposito G,et al.Phosphorylation Sites in Protein Kinases and Phosphatases Regulated by Formyl Peptide Receptor 2 Signaling[J].Int J Mol Sci,2020,21(11):3818.[21]Hume S,Grou CP,Lascaux P,et al.The NUCKS1-SKP2-p21/p27 axis controls S phase entry[J].Nat Commun,2021,12(1):6959.[22]Hu H,Zhu J,Zhong Y,et al.PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway[J].Ann Transl Med,2021,9(5):410.[23]Qiu F,Chen J,Cao J,et al.Low intensity low frequency ultrasound enhances the chemosensitivity of gemcitabine resistant ASPC-1 cells via PI3K/AKT/NF-κB pathway mediated ABC transporters[J].Oncol Rep,2020,44(3):1158-1168. [24]Park JH,Jung KH,Kim SJ,et al.Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer[J].Oncotarget,2017,8(68):112893-112906.[25]Liu S,Zhao S,Dong Y,et al.Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer[J].Cancer Chemother Pharmacol,2021,87(3):415-423.[26]Wang Z,Luo G,Qiu Z.Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine[J].Oncol Lett,2020,19(3):1999-2004.[27]Lucero-Acu?觡a A,Jeffery JJ,Abril ER,et al.Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer[J].Int J Nanomedicine,2014,9:5653-5665.[28]Joka M,Boeck S,Zech CJ,et al.Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer:a dose-finding study[J].Anticancer Drugs,2014,25(9):1095-1101.[29]Kordes S,Klümpen HJ,Weterman MJ,et al.Phase Ⅱ study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer[J].Cancer Chemother Pharmacol,2015,75(6):1135-1141.[30]Gao S,Pu N,Yin H,et al.Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70[J].Ther Adv Med Oncol,2020,12:1758835920953728.
相似文献/References:
[1]赵霓姗.胰腺癌主要危险因素及作用机制研究[J].医学信息,2020,33(03):56.[doi:10.3969/j.issn.1006-1959.2020.03.017]
ZHAO Ni-shan.Study on the Main Risk Factors and Mechanism of Pancreatic Cancer[J].Journal of Medical Information,2020,33(02):56.[doi:10.3969/j.issn.1006-1959.2020.03.017]
[2]张文娟,边 伟,王炳超,等.miR-381在胰腺癌患者组织及外周血的表达及临床价值[J].医学信息,2021,34(06):111.[doi:10.3969/j.issn.1006-1959.2021.06.028]
ZHANG Wen-juan,BIAN Wei,WANG Bing-chao,et al.The Expression and Clinical Value of miR-381 in Tissues and Peripheral Blood of Patients with Pancreatic Cancer[J].Journal of Medical Information,2021,34(02):111.[doi:10.3969/j.issn.1006-1959.2021.06.028]
[3]王宇路,王苏平,赵雪梅,等.磁共振胰胆管成像对肿块型胰腺炎与胰腺癌的诊断价值[J].医学信息,2021,34(13):176.[doi:10.3969/j.issn.1006-1959.2021.13.049]
WANG Yu-lu,WANG Su-ping,ZHAO Xue-mei,et al.The Value of Magnetic Resonance Cholangiopancreatography in the Differential Diagnosis of Mass Forming ChronicPancreatitis and Pancreatic Cancer[J].Journal of Medical Information,2021,34(02):176.[doi:10.3969/j.issn.1006-1959.2021.13.049]
[4]邓裕山,沈国双.AP1基因家族与恶性肿瘤的关系研究[J].医学信息,2022,35(06):56.[doi:10.3969/j.issn.1006-1959.2022.06.014]
DENG Yu-shan,SHEN Guo-shuang.Study on the Relationship Between AP1 Gene Family and Malignant Tumors[J].Journal of Medical Information,2022,35(02):56.[doi:10.3969/j.issn.1006-1959.2022.06.014]
[5]孙惠昕,贾海晗,王婉莹,等.胰腺癌流行现状和影响因素的研究[J].医学信息,2022,35(11):47.[doi:10.3969/j.issn.1006-1959.2022.11.014]
SUN Hui-xin,JIA Hai-han,WANG Wan-ying,et al.The Prevalence and Influencing Factors of Pancreatic Cancer[J].Journal of Medical Information,2022,35(02):47.[doi:10.3969/j.issn.1006-1959.2022.11.014]
[6]吴昭怡,黄金智,张庆余,等.靶向PI3K/AKT/mTOR通路治疗子宫内膜癌的研究现状[J].医学信息,2022,35(12):68.[doi:10.3969/j.issn.1006-1959.2022.12.016]
WU Zhao-yi,HUANG Jin-zhi,ZHANG Qing-yu,et al.Research Status of Targeted PI3K/AKT/mTOR Pathway in the Treatment of Endometrial Carcinoma[J].Journal of Medical Information,2022,35(02):68.[doi:10.3969/j.issn.1006-1959.2022.12.016]
[7]周国斌,柳登平.磁共振和经腹部彩超对胰腺癌与肿块型胰腺炎的鉴别诊断价值分析[J].医学信息,2022,35(17):99.[doi:10.3969/j.issn.1006-1959.2022.17.026]
ZHOU Guo-bin,LIU Deng-ping.Value of Magnetic Resonance and Transabdominal Ultrasonography in Differential Diagnosis of Pancreatic Carcinoma and Mass-type Pancreatitis[J].Journal of Medical Information,2022,35(02):99.[doi:10.3969/j.issn.1006-1959.2022.17.026]
[8]漆处梅,唐小龙.胰腺癌患者BZW1和BZW2表达水平及其与预后的相关性分析[J].医学信息,2022,35(21):26.[doi:10.3969/j.issn.1006-1959.2022.21.006]
QI Chu-mei,TANG Xiao-long.Expression of BZW1 and BZW2 in Pancreatic Cancer and its Correlation with Prognosis[J].Journal of Medical Information,2022,35(02):26.[doi:10.3969/j.issn.1006-1959.2022.21.006]
[9]王雨娜,吴冬桂,赵 贝.基于数据挖掘AGR2在胰腺癌中的表达及预后潜力[J].医学信息,2022,35(22):9.[doi:10.3969/j.issn.1006-1959.2022.22.002]
WANG Yu-na,WU Dong-gui,ZHAO Bei.Expression and Prognostic Potential of AGR2 in Pancreatic Cancer Based on Data Mining[J].Journal of Medical Information,2022,35(02):9.[doi:10.3969/j.issn.1006-1959.2022.22.002]
[10]刘 基,孙振纲,邓 岩,等.炎症对胰腺癌患者预后的评估及免疫状态的影响[J].医学信息,2023,36(05):13.[doi:10.3969/j.issn.1006-1959.2023.05.003]
LIU Ji,SUN Zhen-gang,DENG Yan,et al.Effects of Inflammation on Prognosis and Immune Status in Patients with Pancreatic Adenocarcinoma[J].Journal of Medical Information,2023,36(02):13.[doi:10.3969/j.issn.1006-1959.2023.05.003]